[
 {
  "trial": "T005",
  "source": "abstract",
  "arms": {
   "Group A (ketamine)": {
    "randomized": "35",
    "analysed": null
   },
   "Group B (propofol and fentanyl)": {
    "randomized": "35",
    "analysed": null
   }
  },
  "depression": [
   {
    "measure": "Hamilton Depression Rating (HDR) score",
    "day": -1,
    "form": "mean_sd",
    "location": "abstract",
    "values": {
     "Group A (ketamine)": {
      "mean": "12.7",
      "sd": "5.4",
      "n": null
     },
     "Group B (propofol and fentanyl)": {
      "mean": "12.3",
      "sd": "6.0",
      "n": null
     }
    }
   },
   {
    "measure": "Hamilton Depression Rating (HDR) score",
    "day": 1,
    "form": "mean_sd",
    "location": "abstract",
    "values": {
     "Group A (ketamine)": {
      "mean": "9.9",
      "sd": "4.1",
      "n": null
     },
     "Group B (propofol and fentanyl)": {
      "mean": "14.4",
      "sd": "3.8",
      "n": null
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": null,
  "registration": null,
  "note": "Abstract only. The abstract prints values as mean +/- without saying SD or SE; recorded as mean_sd. Baseline HDR was measured 2 days before surgery (coded day -1); follow-up 1 day after surgery. Number analysed not given. Pain scores were reported only at 8 and 16 h after the end of anesthesia (Group A 26.6 +/- 8.7 and 24.9 +/- 8.2; Group B 34.3 +/- 12.0 and 31.1 +/- 8.8), outside 18-30 h, so left out. Group C (25 non-depressed patients, not randomized) not extracted. No adverse events reported."
 },
 {
  "trial": "T011",
  "source": "abstract",
  "arms": {
   "Group K": {
    "randomized": null,
    "analysed": null
   },
   "Group C": {
    "randomized": null,
    "analysed": null
   }
  },
  "depression": [],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": null,
  "registration": null,
  "note": "Abstract only, with no numbers for any outcome: 120 patients were randomized to group K and group C (per-arm numbers not given). PHQ-9 (1 day before surgery, postoperative days 1 and 5), VAS pain, and complications are described only qualitatively (postoperative PHQ-9 lower in group K, P < 0.05)."
 },
 {
  "trial": "T016",
  "source": "fulltext",
  "arms": {
   "Lo-K": {
    "randomized": null,
    "analysed": "226"
   },
   "Hi-K": {
    "randomized": null,
    "analysed": "223"
   },
   "Placebo (P)": {
    "randomized": null,
    "analysed": "221"
   }
  },
  "depression": [
   {
    "measure": "PHQ-8",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 2 (Preoperative PHQ-8 score, Median (IQR))",
    "values": {
     "Lo-K": {
      "median": "2",
      "q1": "0",
      "q3": "6",
      "n": "226"
     },
     "Hi-K": {
      "median": "2",
      "q1": "0",
      "q3": "5",
      "n": "223"
     },
     "Placebo (P)": {
      "median": "2",
      "q1": "0",
      "q3": "5",
      "n": "221"
     }
    }
   },
   {
    "measure": "PHQ-8",
    "day": -1,
    "form": "count",
    "definition": "PHQ-8 ≥ 10 (symptoms suggestive of depression)",
    "location": "Table 3 (Preoperative)",
    "values": {
     "Lo-K": {
      "events": "24",
      "n": "226"
     },
     "Hi-K": {
      "events": "22",
      "n": "223"
     },
     "Placebo (P)": {
      "events": "18",
      "n": "221"
     }
    }
   },
   {
    "measure": "PHQ-8",
    "day": 3,
    "form": "count",
    "definition": "PHQ-8 ≥ 10 (symptoms suggestive of depression)",
    "location": "Table 3 (POD3)",
    "values": {
     "Lo-K": {
      "events": "32",
      "n": "180"
     },
     "Hi-K": {
      "events": "29",
      "n": "169"
     },
     "Placebo (P)": {
      "events": "23",
      "n": "156"
     }
    }
   },
   {
    "measure": "PHQ-8",
    "day": 30,
    "form": "count",
    "definition": "PHQ-8 ≥ 10 (symptoms suggestive of depression)",
    "location": "Table 3 (POD30)",
    "values": {
     "Lo-K": {
      "events": "9",
      "n": "130"
     },
     "Hi-K": {
      "events": "14",
      "n": "128"
     },
     "Placebo (P)": {
      "events": "24",
      "n": "137"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": null,
  "registration": {
   "number": "NCT01690988",
   "date": null
  },
  "note": "Secondary analysis of PODCAST. Arm numbers are those analysed (Tables 1-2 'Sample size' 221/226/223 of 670); per-arm randomized numbers are only in Fig. 1, which is not reproduced. Baseline PHQ-8: Table 2's 'Mean (sd)' row prints 3.1 (0-5), 3.6 (0-6), 3.3 (0-5) for Placebo, Lo-K, Hi-K (all groups 3.3 (3.9)); the parenthesised values repeat the IQRs, so no usable SD is printed and the Median (IQR) row was taken instead. POD30 is 'approximately 1 month after surgery'. Continuous postoperative PHQ-8 is given only as combined ketamine (Lo-K plus Hi-K) vs placebo Hodges-Lehmann median differences: POD3 0 (95% CI -1.0 to 1.0, P=0.773), POD30 0 (95% CI 0.0-1.0, P=0.271); per-group scores are only in Fig. 2 (no printed values), so not recorded. Methods say 165 missing at POD3 and 375 at POD30; Table 3 has 505 and 395 assessed of 670. No adverse events, enrollment dates, or blinding check in this report."
 },
 {
  "trial": "T024",
  "source": "fulltext",
  "arms": {
   "R (ropivacaine alone)": {
    "randomized": null,
    "analysed": "40"
   },
   "RS (ropivacaine with IV S-ketamine)": {
    "randomized": null,
    "analysed": "40"
   }
  },
  "depression": [
   {
    "measure": "EPDS at discharge",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 1 (EPDS scores at admission)",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "3.5",
      "sd": "2.5",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "2.9",
      "sd": "2.3",
      "n": "40"
     }
    }
   },
   {
    "measure": "EPDS at discharge",
    "day": null,
    "form": "mean_sd",
    "location": "Table 4 (EPDS scores at discharge)",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "4.1",
      "sd": "3.0",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "2.3",
      "sd": "2.5",
      "n": "40"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "analgesic effect at 24 and 48 h",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 4 (Resting VAS at 24H)",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "3.4",
      "sd": "0.9",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "1.4",
      "sd": "1.1",
      "n": "40"
     }
    }
   },
   {
    "measure": "analgesic effect at 24 and 48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 4 (Resting VAS at 48H)",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "1.8",
      "sd": "0.7",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "0.7",
      "sd": "0.8",
      "n": "40"
     }
    }
   },
   {
    "measure": "Mobile VAS",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 4 (Mobile VAS at 24H)",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "5.9",
      "sd": "1.3",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "3.8",
      "sd": "1.3",
      "n": "40"
     }
    }
   },
   {
    "measure": "Mobile VAS",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 4 (Mobile VAS at 48H)",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "3.4",
      "sd": "1.1",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "2.2",
      "sd": "1.1",
      "n": "40"
     }
    }
   },
   {
    "measure": "PCA times",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 4 (PCA times during 24H)",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "2.2",
      "sd": "2.3",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "1.7",
      "sd": "1.8",
      "n": "40"
     }
    }
   },
   {
    "measure": "PCA times",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 4 (PCA times during 24-48H)",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "0.7",
      "sd": "0.8",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "0.4",
      "sd": "0.9",
      "n": "40"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 4, Peri-operative outcomes",
    "values": {
     "R (ropivacaine alone)": {
      "nightmare": "0",
      "visual": "0",
      "dizziness": "1"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "nightmare": "25",
      "visual": "0",
      "dizziness": "21"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-01",
   "end": "2021-04"
  },
  "registration": {
   "number": "ChiCTR2000040375",
   "date": "2020-11-28"
  },
  "note": "Sequential (biased-coin up-and-down) dose-finding study of spinal ropivacaine with IV S-ketamine 0.15 mg/kg or saline 1 min before surgery. 85 women recruited; 40 per group analysed; per-arm randomized numbers only in Fig. 1 (not reproduced). EPDS 'at admission' was completed the day before surgery (day -1) and is recorded under the design's only EPDS name ('EPDS at discharge'); 'EPDS scores at discharge' has no stated day, so day is null. The design's one pain measure ('analgesic effect at 24 and 48 h') is reported as three Table 4 items: resting VAS (recorded under the design's name), mobile VAS and PCA times (under the source's names). 'PCA times during 24-48H' is the count within 24-48 h, not cumulative to 48 h. Adverse events are Table 4 'Peri-operative outcomes' in women awake under spinal-epidural anaesthesia, coded intraoperative; 'Dreaming' coded as nightmare (the source does not say the dreams were unpleasant); 'Blurred vision' coded as visual. Enrollment period is from Methods ('recruited during January 2021 and April 2021')."
 },
 {
  "trial": "T026",
  "source": "fulltext",
  "arms": {
   "Group C": {
    "randomized": "30",
    "analysed": "30"
   },
   "Group K": {
    "randomized": "30",
    "analysed": "30"
   }
  },
  "depression": [
   {
    "measure": "Profile of Mood States (POMS)",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 4 (Total depression subscale, Pre)",
    "values": {
     "Group C": {
      "mean": "8.4",
      "sd": "2.8",
      "n": "30"
     },
     "Group K": {
      "mean": "8.1",
      "sd": "2.3",
      "n": "30"
     }
    }
   },
   {
    "measure": "Profile of Mood States (POMS)",
    "day": 0,
    "form": "mean_sd",
    "location": "Table 4 (Total depression subscale, Post)",
    "values": {
     "Group C": {
      "mean": "10.2",
      "sd": "3.4",
      "n": "30"
     },
     "Group K": {
      "mean": "5.3",
      "sd": "1.9",
      "n": "30"
     }
    }
   },
   {
    "measure": "Total POMS",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 4 (Total POMS, Preoperative)",
    "values": {
     "Group C": {
      "mean": "27.8",
      "sd": "9.5",
      "n": "30"
     },
     "Group K": {
      "mean": "28.1",
      "sd": "8.0",
      "n": "30"
     }
    }
   },
   {
    "measure": "Total POMS",
    "day": 0,
    "form": "mean_sd",
    "location": "Table 4 (Total POMS, Postoperative)",
    "values": {
     "Group C": {
      "mean": "37.3",
      "sd": "13.0",
      "n": "30"
     },
     "Group K": {
      "mean": "11.9",
      "sd": "5.4",
      "n": "30"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 5 (Diplopia, Intraoperative)",
    "values": {
     "Group C": {
      "visual": "0"
     },
     "Group K": {
      "visual": "9"
     }
    }
   },
   {
    "window": "postoperative",
    "location": "Table 5 (Diplopia, Postoperative)",
    "values": {
     "Group C": {
      "visual": "0"
     },
     "Group K": {
      "visual": "6"
     }
    }
   },
   {
    "window": "overall",
    "location": "Table 5 (Perioperative psychedelic phenomena)",
    "values": {
     "Group C": {
      "hallucination": "0",
      "dissociation": "0"
     },
     "Group K": {
      "hallucination": "2",
      "dissociation": "6"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2019-07",
   "end": "2020-08"
  },
  "registration": {
   "number": "PACTR201907779292947",
   "date": "2019-07-16"
  },
  "note": "The design's 'Profile of Mood States (POMS)' (code POMS_D) is recorded as the POMS 'Total depression subscale' (Table 4); the paper's primary outcome, 'Total POMS' (total mood disturbance), is recorded separately under the source's name. POMS was completed preoperatively (day -1) and 2 h postoperatively (day 0). Per-arm randomized numbers are not stated outright: 60 were randomized 1:1 and every table gives N = 30 per arm with no losses reported. Table 5 also gives headache (intraoperative 6 vs 0, postoperative 7 vs 6) and the psychedelic phenomena relaxation 25 vs 0, euphoria 7 vs 0 and dysphoria 1 vs 0 (Group K vs Group C), which have no codebook category. Psychedelic phenomena were assessed intraoperatively (during infusion) and/or postoperatively, coded overall. Diplopia coded as visual. No pain scores reported."
 },
 {
  "trial": "T030",
  "source": "fulltext",
  "arms": {
   "Group S (esketamine)": {
    "randomized": "105",
    "analysed": "102"
   },
   "Group L (saline)": {
    "randomized": "105",
    "analysed": "100"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": -1,
    "form": "count",
    "definition": "EPDS ≥ 9 (post-partum depression)",
    "location": "Table 2 (Pre-partum day 1)",
    "values": {
     "Group S (esketamine)": {
      "events": "26",
      "n": "102"
     },
     "Group L (saline)": {
      "events": "31",
      "n": "100"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "count",
    "definition": "EPDS ≥ 9 (post-partum depression)",
    "location": "Table 2 (Post-partum week 1)",
    "values": {
     "Group S (esketamine)": {
      "events": "4",
      "n": "102"
     },
     "Group L (saline)": {
      "events": "2",
      "n": "100"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 14,
    "form": "count",
    "definition": "EPDS ≥ 9 (post-partum depression)",
    "location": "Table 2 (Post-partum week 2)",
    "values": {
     "Group S (esketamine)": {
      "events": "2",
      "n": "102"
     },
     "Group L (saline)": {
      "events": "1",
      "n": "100"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 28,
    "form": "count",
    "definition": "EPDS ≥ 9 (post-partum depression)",
    "location": "Table 2 (Post-partum week 4)",
    "values": {
     "Group S (esketamine)": {
      "events": "2",
      "n": "102"
     },
     "Group L (saline)": {
      "events": "1",
      "n": "100"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 3, 5 min after administration",
    "values": {
     "Group S (esketamine)": {
      "dizziness": "50",
      "hallucination": "28",
      "visual": "0"
     },
     "Group L (saline)": {
      "dizziness": "4",
      "hallucination": "0",
      "visual": "0"
     }
    }
   },
   {
    "window": "intraoperative",
    "location": "Table 3, 15 min after administration",
    "values": {
     "Group S (esketamine)": {
      "dizziness": "66",
      "hallucination": "2"
     },
     "Group L (saline)": {
      "dizziness": "2",
      "hallucination": "0"
     }
    }
   },
   {
    "window": "emergence",
    "location": "Table 3, when leaving the operating room",
    "values": {
     "Group S (esketamine)": {
      "dizziness": "34",
      "hallucination": "0",
      "visual": "1"
     },
     "Group L (saline)": {
      "dizziness": "0",
      "hallucination": "0",
      "visual": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": null,
  "registration": {
   "number": "ChiCTR2100054332",
   "date": null
  },
  "note": "Post-partum depression defined as EPDS score of nine or more; EPDS taken 1 day before delivery (coded day -1) and by telephone 1, 2 and 4 weeks after delivery. The 8 lost to follow-up were excluded, so all counts use the analysed n of 102 and 100 (Table 2 header). EPDS scores (Fig. 3) and NRS at rest and when coughing at 4, 8, 24 and 48 h (Fig. 2) appear only in figures without printed values (text: cough NRS lower in Group S at 24 h, p = 0.016). Table 3 adverse events: two intraoperative time points (5 min and 15 min after esketamine, given 5 min after delivery under spinal anaesthesia) recorded as separate entries, and 'when leaving the operating room' coded emergence. Diplopia and blurred vision are reported separately: both 0 in both arms at 5 min; at 15 min Group S diplopia 2 and blurred vision 1 (Group L 0 and 0), so visual is left out there because the overlap is unknown; when leaving the OR Group S diplopia 0 and blurred vision 1, Group L 0 and 0. Nausea, headache and vomiting are also in Table 3. Enrollment dates not reported."
 },
 {
  "trial": "T059",
  "source": "fulltext",
  "arms": {
   "Treatment Arm": {
    "randomized": "30",
    "analysed": "28"
   },
   "Control Arm (saline)": {
    "randomized": "30",
    "analysed": "27"
   }
  },
  "depression": [
   {
    "measure": "Self-rating Depression Scale (SDS), at admission and discharge",
    "day": null,
    "form": "median_iqr",
    "location": "Table 3 (Median SDS on Day 28 (Q25, Q75))",
    "values": {
     "Treatment Arm": {
      "median": "49.8",
      "q1": "43.1",
      "q3": "56.5",
      "n": "28"
     },
     "Control Arm (saline)": {
      "median": "53.1",
      "q1": "47.3",
      "q3": "59.0",
      "n": "27"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": {
   "start": "2020-09",
   "end": "2022-12"
  },
  "registration": {
   "number": "ChiCTR2000034069",
   "date": "2020-06-22"
  },
  "note": "SDS is printed only for Day 28 (Table 3); Methods say SDS on admission and discharge, but no admission values are printed. The trial counts days from admission (Day 0 = admission); esketamine was given at induction for each of the first 3 surgeries and in the analgesic pump for up to 7 postoperative days, and the day of the first surgery after admission is not given, so day is null (Day 28 after admission). Modified ITT: 3 withdrew consent and 2 were excluded for continuous sedation in ICU (arms not given). Pain: NPRr and NPRm only in Fig. 2 (medians with IQR bars, no printed values). Table 2 gives 'Cases with NPRr > 3' 3 (10.7%) vs 6 (22.2%), 'Cases with NPRm > 3' 9 (32.1%) vs 17 (65.4%), and 'Postoperative daily opioid consumption (mg)' (IV morphine equivalents) 26.0 (16.3, 32.5) vs 35.0 (26.4, 50.9) as median (Q25, Q75), all over the whole postoperative period rather than at 24 or 48 h, so left out; SAE (the primary outcome) is not a pain score at 24/48 h. No psychotomimetic adverse events reported."
 },
 {
  "trial": "T067",
  "source": "fulltext",
  "arms": {
   "Control group (placebo)": {
    "randomized": "45",
    "analysed": "42"
   },
   "Low esketamine group (0.2 mg/kg)": {
    "randomized": "45",
    "analysed": "42"
   },
   "High esketamine group (0.5 mg/kg)": {
    "randomized": "45",
    "analysed": "45"
   }
  },
  "depression": [
   {
    "measure": "HADS-D",
    "day": -1,
    "form": "count",
    "definition": "HADS-D ≥ 8 (depressive symptoms)",
    "location": "Table 3 (Depression incidence, Preoperative)",
    "values": {
     "Control group (placebo)": {
      "events": "15",
      "n": "42"
     },
     "Low esketamine group (0.2 mg/kg)": {
      "events": "20",
      "n": "42"
     },
     "High esketamine group (0.5 mg/kg)": {
      "events": "16",
      "n": "45"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 1,
    "form": "count",
    "definition": "HADS-D ≥ 8 (depressive symptoms)",
    "location": "Table 3 (Depression incidence, POD1)",
    "values": {
     "Control group (placebo)": {
      "events": "12",
      "n": "42"
     },
     "Low esketamine group (0.2 mg/kg)": {
      "events": "5",
      "n": "42"
     },
     "High esketamine group (0.5 mg/kg)": {
      "events": "1",
      "n": "45"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 3,
    "form": "count",
    "definition": "HADS-D ≥ 8 (depressive symptoms)",
    "location": "Table 3 (Depression incidence, POD3)",
    "values": {
     "Control group (placebo)": {
      "events": "2",
      "n": "42"
     },
     "Low esketamine group (0.2 mg/kg)": {
      "events": "0",
      "n": "42"
     },
     "High esketamine group (0.5 mg/kg)": {
      "events": "1",
      "n": "45"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 2 (Postoperative Agitation); Results 3.6 text for the zeros",
    "values": {
     "Control group (placebo)": {
      "agitation": "3",
      "nightmare": "0",
      "dizziness": "0",
      "hallucination": "0"
     },
     "Low esketamine group (0.2 mg/kg)": {
      "agitation": "5",
      "nightmare": "0",
      "dizziness": "0",
      "hallucination": "0"
     },
     "High esketamine group (0.5 mg/kg)": {
      "agitation": "2",
      "nightmare": "0",
      "dizziness": "0",
      "hallucination": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-06",
   "end": "2022-07"
  },
  "registration": {
   "number": "ChiCTR2100047067",
   "date": null
  },
  "note": "HADS-D scores appear only in Fig. 3 (no printed values); the counts are depressive symptoms defined as HADS-D >= 8 (Table 3), assessed the day before surgery (POD-1), POD1 and POD3. VAS at 2, 24, 48 and 72 h is likewise only in Fig. 3, so no pain entries. Postoperative agitation counts are from Table 2 (printed as numbers only). The zeros for nightmare, dizziness and hallucination come from the text (Results 3.6: 'no participants reported experiencing nightmares, dizziness, itching, urinary retention, convulsions, or hallucinations'), with no window stated; coded postoperative with the agitation counts."
 },
 {
  "trial": "T074",
  "source": "fulltext",
  "arms": {
   "Esketamine group (group E)": {
    "randomized": "50",
    "analysed": "50"
   },
   "Control group (group C)": {
    "randomized": "50",
    "analysed": "48"
   }
  },
  "depression": [
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": -1,
    "form": "count",
    "definition": "EPDS category 'Depression' (Table 4; cutoffs not stated; the separate 'Mild' category is not included)",
    "location": "Table 4 (Preoperative depression)",
    "values": {
     "Esketamine group (group E)": {
      "events": "0",
      "n": "50"
     },
     "Control group (group C)": {
      "events": "3",
      "n": "48"
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 2,
    "form": "count",
    "definition": "EPDS category 'Depression' (Table 4; cutoffs not stated; the separate 'Mild' category is not included)",
    "location": "Table 4 (Postoperative depression)",
    "values": {
     "Esketamine group (group E)": {
      "events": "0",
      "n": "50"
     },
     "Control group (group C)": {
      "events": "1",
      "n": "48"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "maximum NRS pain within 24 h",
    "day": 1,
    "form": "median_iqr",
    "location": "Results, text (maximum NRS within 24 h)",
    "values": {
     "Esketamine group (group E)": {
      "median": "5",
      "q1": "4",
      "q3": "5",
      "n": null
     },
     "Control group (group C)": {
      "median": "6",
      "q1": "5",
      "q3": "6",
      "n": null
     }
    }
   },
   {
    "measure": "NRS moving incision pain (0-6, 6-12, 12-24 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results, values printed with Fig 3 (Moving incision pain, 12-24 h)",
    "values": {
     "Esketamine group (group E)": {
      "median": "4",
      "q1": "4",
      "q3": "5",
      "n": null
     },
     "Control group (group C)": {
      "median": "5",
      "q1": "4",
      "q3": "5",
      "n": null
     }
    }
   },
   {
    "measure": "NRS rest incision pain (0-6, 6-12, 12-24 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results, values printed with Fig 3 (Rest incision pain, 12-24 h)",
    "values": {
     "Esketamine group (group E)": {
      "median": "2",
      "q1": "1",
      "q3": "2",
      "n": null
     },
     "Control group (group C)": {
      "median": "2",
      "q1": "1",
      "q3": "3",
      "n": null
     }
    }
   },
   {
    "measure": "NRS visceral pain (0-6, 6-12, 12-24 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results, values printed with Fig 3 (Visceral pain, 12-24 h)",
    "values": {
     "Esketamine group (group E)": {
      "median": "4",
      "q1": "2.75",
      "q3": "4.25",
      "n": null
     },
     "Control group (group C)": {
      "median": "5",
      "q1": "4",
      "q3": "5.75",
      "n": null
     }
    }
   },
   {
    "measure": "PCIA presses, rescue analgesic dose, total PCIA consumption",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3 (12-24 h postoperatively PCIA consumption (mL))",
    "values": {
     "Esketamine group (group E)": {
      "median": "34.00",
      "q1": "30.00",
      "q3": "43.50",
      "n": "50"
     },
     "Control group (group C)": {
      "median": "33.00",
      "q1": "27.00",
      "q3": "44.25",
      "n": "48"
     }
    }
   },
   {
    "measure": "NOC of PCIA (times)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3 (12-24 h postoperatively NOC of PCIA (times))",
    "values": {
     "Esketamine group (group E)": {
      "median": "4.00",
      "q1": "2.00",
      "q3": "7.25",
      "n": "50"
     },
     "Control group (group C)": {
      "median": "3.00",
      "q1": "2.00",
      "q3": "6.75",
      "n": "48"
     }
    }
   },
   {
    "measure": "pressure pain threshold and tolerance (30 min, 24 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results, text (PPT (kgf), T2)",
    "values": {
     "Esketamine group (group E)": {
      "median": "2.03",
      "q1": "1.6",
      "q3": "2.83",
      "n": null
     },
     "Control group (group C)": {
      "median": "2.15",
      "q1": "1.8",
      "q3": "2.8",
      "n": null
     }
    }
   },
   {
    "measure": "PTO (kgf)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results, text (PTO (kgf), T2)",
    "values": {
     "Esketamine group (group E)": {
      "median": "3.88",
      "q1": "2.62",
      "q3": "4.83",
      "n": null
     },
     "Control group (group C)": {
      "median": "3.85",
      "q1": "3.33",
      "q3": "4.92",
      "n": null
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 5",
    "values": {
     "Esketamine group (group E)": {
      "dizziness": "4",
      "nightmare": "5",
      "visual": "1"
     },
     "Control group (group C)": {
      "dizziness": "3",
      "nightmare": "2",
      "visual": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2023-12-12",
   "end": "2025-04-18"
  },
  "registration": {
   "number": "ChiCTR2300078310",
   "date": null
  },
  "note": "EPDS (Table 4) is reported in three categories, No / Mild / Depression, without cutoffs; the counts recorded are the 'Depression' category. 'Mild' was E 13 vs C 8 preoperatively and E 2 vs C 7 on postoperative day 2 ('No' 37 vs 37 and 48 vs 40); the text calls postpartum depression lower in group E (P = 0.038) on that whole distribution, so 'any depression' would be Mild plus Depression (not computed here). Two group C participants withdrew (3 h and 8 h postoperatively). Pain was only measured to 24 h: 'maximum NRS pain within 24 h' and the maximum NRS within the 12-24 h interval (rest, moving, visceral) coded day 1; the 0-6 and 6-12 h values are left out. Group C's visceral 12-24 h q3 is printed '5. 75' (recorded 5.75). Group C's rest 12-24 h IQR is printed '[1, 3]'. Table 3 PCIA values are per interval; the 12-24 h interval (not cumulative 0-24 h) coded day 1, with consumption (mL) under the design's measure name and number of compressions under 'NOC of PCIA (times)'; rescue analgesia was one group C patient (tramadol 150 mg). PPT and PTO are printed for T0, T1, T2 without definitions; Methods measure them preoperatively and at 30 min and 24 h after surgery, so T2 is taken as 24 h; PPT under the design's measure name, PTO under 'PTO (kgf)'. n for text-only values is not printed. Side effects were assessed at 24 h postoperatively; diplopia coded as visual; drowsiness and nausea/vomiting also reported."
 },
 {
  "trial": "T080",
  "source": "fulltext",
  "arms": {
   "Low-dose group (L)": {
    "randomized": "75",
    "analysed": "75"
   },
   "High-dose group (H)": {
    "randomized": "75",
    "analysed": "75"
   },
   "Control group (C)": {
    "randomized": "75",
    "analysed": "75"
   }
  },
  "depression": [
   {
    "measure": "HAMD-17",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 3 (Before surgery)",
    "values": {
     "Low-dose group (L)": {
      "mean": "12.3",
      "sd": "6.0",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "12.6",
      "sd": "5.8",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "12.7",
      "sd": "5.4",
      "n": "75"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 3 (Day 1)",
    "values": {
     "Low-dose group (L)": {
      "mean": "10.3",
      "sd": "4.2",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "10.1",
      "sd": "4.1",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "14.4",
      "sd": "3.8",
      "n": "75"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 3,
    "form": "mean_sd",
    "location": "Table 3 (Day 3)",
    "values": {
     "Low-dose group (L)": {
      "mean": "10.5",
      "sd": "5.8",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "9.2",
      "sd": "3.6",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "13.5",
      "sd": "4.2",
      "n": "75"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 3 (Day 7)",
    "values": {
     "Low-dose group (L)": {
      "mean": "11.9",
      "sd": "5.6",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "11.6",
      "sd": "3.9",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "12.1",
      "sd": "4.7",
      "n": "75"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "VAS (4, 8, 12, 24, 48 h)",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 5 (VAS, T4 (24 h))",
    "values": {
     "Low-dose group (L)": {
      "mean": "2.1",
      "sd": "0.9",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "1.8",
      "sd": "1.0",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "1.7",
      "sd": "1.0",
      "n": "75"
     }
    }
   },
   {
    "measure": "VAS (4, 8, 12, 24, 48 h)",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 5 (VAS, T5 (48 h))",
    "values": {
     "Low-dose group (L)": {
      "mean": "1.2",
      "sd": "0.8",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "1.1",
      "sd": "0.9",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "0.9",
      "sd": "0.3",
      "n": "75"
     }
    }
   },
   {
    "measure": "total postoperative sufentanil consumption over 48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 7 (Sufentanil dosage (μg))",
    "values": {
     "Low-dose group (L)": {
      "mean": "69.2",
      "sd": "4.8",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "66.7",
      "sd": "5.1",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "83.0",
      "sd": "5.6",
      "n": "75"
     }
    }
   },
   {
    "measure": "PCA compressions",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 7 (PCA compressions)",
    "values": {
     "Low-dose group (L)": {
      "mean": "5.3",
      "sd": "2.8",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "2.1",
      "sd": "1.2",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "11.5",
      "sd": "3.5",
      "n": "75"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 9",
    "values": {
     "Low-dose group (L)": {
      "dizziness": "10",
      "nightmare": "2",
      "agitation": "0"
     },
     "High-dose group (H)": {
      "dizziness": "10",
      "nightmare": "2",
      "agitation": "0"
     },
     "Control group (C)": {
      "dizziness": "7",
      "nightmare": "0",
      "agitation": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-09",
   "end": "2024-06"
  },
  "registration": null,
  "note": "Esketamine (0.5 or 0.75 mg/kg over 24 h) or saline was infused from the end of surgery. Analysis was ITT with LOCF for dropouts' HAMD; every table gives N = 75 per group and the number of dropouts is not reported. Sufentanil and PCA compressions are totals over the 48 h analgesic pump (coded day 2). Intraoperative sufentanil (Table 2) precedes the postoperative infusion (day 0) and is left out. 'Delirium' (Table 9) coded as agitation. Possible data-integrity concern: group C's HAMD before surgery (12.7 +/- 5.4) and on day 1 (14.4 +/- 3.8) and group L's before surgery (12.3 +/- 6.0) are identical to values printed in the T005 abstract (Kudoh 2002), and the 'preliminary experimental results' quoted in Methods for day 3 (control 13.5 +/- 4.2, esketamine 10.5 +/- 5.8) are identical to this trial's own day-3 results for C and L. Table 2 labels its third column 'L Group' (presumably H). The text gives the day-3 H vs L CI as [-2.8, -0.2] and Table 4 as [-2.8, 0.2]. No registration number given; enrollment period from Methods ('from September 2021 to June 2024')."
 }
]